PPD Global Central Labs BVBA

What PPD Global Central Labs BVBA does

PPD Global Central Labs BVBA is a Belgian-domiciled (BVBA), wholly-owned subsidiary of Thermo Fisher Scientific (NYSE: TMO) and a constituent of its Clinical Research Services segment following Thermo Fisher's 2021 acquisition of PPD. The entity operates as part of PPD's global Contract Research Organization (CRO) platform, providing central laboratory and biomarker testing services that underpin clinical trials sponsored by pharmaceutical and biotechnology companies. Its core product surface spans Clinical Development Services (Phase II-IV trial management, biostatistics, clinical data management, pharmacovigilance, regulatory affairs), PPD Laboratory Services (bioanalytical LC/MS, central lab with CAP/BSL-2 accreditation in Suzhou, China, GMP lab, biomarker, and vaccine sciences), PPD Evidera (real-world evidence and health economics/market access), proprietary real-world data assets (PPD CorEvitas clinical registries and PPD Vestrum Health), and Digital Drug Development Solutions (Preclarus analytics platform, Clinical Decision Suite, and Clinical Trial Forecasting Suite with predictive analytics). Complementary service lines include Functional Service Partnership (FSP) Solutions, Scientific Resourcing (embedded teams of 100+ scientists in client labs), PPD Biotech Solutions for small/mid-sized biotech, Biosimilar Development Services, PPD Translate Solutions, and Medical Communications, supported by therapeutic expertise across more than 20 areas including cardiovascular, oncology, immunology, neurology, metabolic disorders, rare diseases, and vaccines.

The company monetizes primarily through multi-year, contract-based professional services and managed-services (FSP) engagements, with pricing determined by study complexity, therapeutic area, phase, geographic scope, and number of patients or sites. Customer segments are dual-tracked: large pharmaceutical enterprises (with named reference to a top-10 pharma relationship) and small- to mid-sized biotechs, plus a secondary government and public health channel. Distribution is enterprise field sales, leveraging Thermo Fisher's global network for cross-sell, a Suzhou-based regional lab with five Chinese offices (Beijing, Shanghai, Guangzhou, Shenyang, Hong Kong), and a network of 160+ dedicated cardiovascular research sites and 2,200+ global top performer sites. Strategic partnerships with GCTP (cardiovascular MACE adjudication) and Olink (cardiac biomarkers), combined with CAP, BSL-2, GCP, and GLP certifications, reinforce the moat in cardiovascular outcomes trials, biosimilar development (20+ years of experience supporting all top 10 selling biologics), and vaccine sciences.

Name

PPD Global Central Labs BVBA

Legal name

PPD Global Central Labs BVBA

Website

https://ppdi.com

Company type

Public

Operating status

Operating

Short description

PPD Global Central Labs BVBA is a Belgian subsidiary of Thermo Fisher Scientific's PPD CRO, providing central laboratory, bioanalytical, biomarker, and vaccine sciences testing for global pharmaceutical and biotechnology clinical trials.

Ownership category

akta.pro rank

Product category

Clinical Laboratory Services (Contract Research Organization)

NAICS

Medical Laboratories (621511), Scientific Research and Development Services (5417)

SIC

Services-Medical Laboratories (8071), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Clinical Research & Trial Central Laboratories (HLAFAMAL)

akta.pro secondary industries

Central Laboratory Services (Core Lab Operations) (HLAGAEAA), Clinical Operations & Monitoring FSP (CRA/CTM/Start-up) (HLAGAOAA)

Keywords

• Central laboratory services
• Biomarker testing services
• Clinical trial management
• Bioanalytical laboratory testing
• Vaccine sciences testing

Headquarters

HQ city

Zaventem

HQ country

Belgium

HQ region

Europe

Offices7 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure, Supply Chain

Revenue model

1. Clinical Research Services: Full-service contract research organization providing end-to-end clinical trial management from Phase I through Phase IV, including regulatory affairs, pharmacovigilance, and clinical operations.
2. Scientific Resourcing / FSP: Flexible laboratory resourcing model embedding scientific talent and operational teams directly into client facilities. Provides single specialists or fully integrated teams of 100+ scientists and staff.
3. Laboratory Services: Central laboratory, bioanalytical, biomarker, GMP, and vaccine sciences laboratory services with global standards and local convenience in China.

Pricing tiers

Go-to-market motion2 records

Distribution channels3 records

Marketing channels8 records

Core offering

PPD Global Central Labs BVBA operates as the central laboratory arm of PPD, providing clinical trial sample testing services including bioanalytical, biomarker, central lab, GMP lab, and vaccine sciences capabilities. Services are delivered through CAP-accredited and BSL-2 certified laboratory facilities, with specialized regional infrastructure in Suzhou, China for local kit-building and Asian clinical trials. The unit supports pharmaceutical and biotechnology sponsors across Phase I–IV clinical development, with deep specialization in cardiovascular outcomes trials, biosimilar development, and vaccine sciences.

Product overview

PPD is a global pharmaceutical Contract Research Organization (CRO) offering an integrated platform of clinical research and laboratory services. The core offering combines Clinical Development Services (Phase II-IV trial management, biostatistics, pharmacovigilance, regulatory affairs) with PPD Laboratory Services (bioanalytical, central, GMP, biomarker, and vaccine sciences labs). The portfolio includes specialized sub-brands like PPD Evidera for Real-World Evidence and Health Economics & Market Access, Digital Drug Development Solutions (Preclarus, Clinical Decision Suite, Clinical Trial Forecasting Suite) for AI-powered analytics, and PPD CorEvitas and Vestrum Health for proprietary real-world data. Flexible resourcing is available through Functional Service Partnership (FSP) Solutions and Scientific Resourcing. Specialized offerings include Biosimilar Development, PPD Biotech Solutions, PPD Translate Solutions, and Medical Communications, all supported by deep therapeutic expertise across 20+ areas.

Differentiator

Problem solved

Functional benefit

Brands

• PPD Evidera: Patient-centered research, health economics, and market access services
• PPD CorEvitas
• PPD Vestrum Health
• Preclarus
• PPD Translate Solutions
• PPD Laboratory Services
• PPD Accelerator Drug Development

Products and services

• Clinical Development Services

Quantifiable outcome

• 99%+ patient retention rates in cardiovascular outcomes trials
• +2 more outcomes

Named customers4 records

Segments4 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability1 record

Feature7 records

Partnerships

Two partnerships are on record, tiered core and minor.

• GCTP (Global Cardiovascular Trial Partners)coreStrategic or Co-development PartnerEvent adjudication partnership for cardiovascular outcomes trials. GCTP provides expertise in major adverse cardiac events (MACE) adjudication, supporting regulatory requirements for cardiovascular drug development programs.
• Academic Research OrganizationsminorStrategic or Co-development PartnerPPD has experience with various academic research organization partnership models for cardiovascular outcomes research, providing strategic collaboration for clinical trial design and execution.

Scale indicators7 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Syneos Health: Syneos is a full-service biopharmaceutical CRO with clinical development and lab services overlap; competes with PPD for global pharma outsourcing contracts including central lab and biomarker work.
• ICON plc: ICON is a top-3 global CRO offering full-service clinical development, central lab, bioanalytical, and FSP services to pharma/biotech, directly competing with PPD across Phase II-IV trials and lab testing.
• Labcorp Drug Development (Fortrea): Spun off from Labcorp in 2023, Fortrea is a leading CRO with deep central laboratory, bioanalytical, and early development services, directly competing with PPD Global Central Labs for global clinical trial lab contracts.
• Parexel International: Parexel is a global CRO with Phase II-IV clinical trial management, bioanalytical, and central lab capabilities that directly compete with PPD Global Central Labs for enterprise pharma/biotech clients.
• IQVIA: IQVIA is the world's largest CRO, offering end-to-end clinical development, central lab services, real-world evidence, and analytics that directly overlap with PPD's clinical trial and laboratory portfolio. Both serve global pharma and biotech sponsors with integrated study execution.
• Medpace: Medpace is a mid-sized full-service CRO focused on Phase II-IV clinical development for small-to-mid biopharma, competing directly with PPD's biotech solutions and central lab offerings.

Emerging players

• Eurofins Scientific: Eurofins is a global lab testing powerhouse with clinical and pharmaceutical testing services that overlap with PPD's central lab and bioanalytical offerings for clinical trial samples.
• WuXi AppTec / WuXi Biologics: WuXi AppTec and WuXi Biologics are leading APAC-based CROs/CDMOs with extensive central lab, bioanalytical, and biologics development capabilities that increasingly compete with PPD's Suzhou-based lab and global trial services.

Broad incumbents

• Charles River Laboratories: Charles River is a larger, established nonclinical CRO and lab services provider with significant overlap in bioanalytical, safety, and biomarker testing for clinical and preclinical studies, competing in adjacent lab service categories.
• Thermo Fisher Scientific (Patheon/CDMO): Thermo Fisher is PPD's parent company and also operates the Patheon CDMO and life sciences services franchises; while not a competitor per se, its broader pharma services portfolio creates both integration upside and internal cannibalization dynamics for PPD.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat7 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xtwitter.com/ppdcro
• YouTubeyoutube.com/PPDCRO
• Facebookfacebook.com/PPDCRO
• LinkedInlinkedin.com/company/ppd
• Instagraminstagram.com/ppdcro

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about PPD Global Central Labs BVBA